Stay updated with breaking news from Through Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire ...
Vertex Pharmaceuticals Inc. (VRTX) Wednesday announced that it has agreed to acquire Alpine Immune Sciences Inc. (ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-sourced denosumab in healthy male study participantsPhase 3 study shows
Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-sourced...
The proposed denosumab biosimilar, SB16, demonstrated pharmacokinetic bioequivalence, as well as equivalent efficacy, safety, and immunogenicity,